



Application No.: 10/042,431

Group 1652

No.:

Filed: October 25, 2001

Examiner: Nashed, Nashaat T.

For: METHOD OF IDENTIFYING INHIBITORS OF THE HUMAN LIPASE
TANGO 294 (as amended)

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

DEPOSIT DECLARATION

Sir:

I, Mario Cloutier, hereby declare that:

1. I am an agent of record in the above-identified patent application.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Address" Mailing Label No.

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker

(type or print name of person certifying)

Date: July 19, 2004

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

2. Plasmids containing clone EpT294, encoding human TANGO 294 polypeptides described in the above-identified patent application, were deposited with the American Type Culture Collection (ATCC®), 10801 University Boulevard, Manassas, VA 20110-2209, on April 20, 1999 under the terms of the Budapest Treaty and assigned (composite) ATCC® Accession Number 207220.


3. Upon granting of a patent on the above-identified patent application, all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed.

I hereby declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the instant patent application or any patent issued thereon.

July 19, 2004

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By 
Mario Cloutier
Limited Recognition Under 37 C.F.R. §10.9(b)
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-577-3522
Facsimile - 617-551-8820



**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATE PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Mario Cloutier is hereby given limited recognition under 37 CFR, 10.9(b) as an employee of Millenium Pharmaceuticals to prepare and prosecute patent applications wherein Millenium Pharmaceuticals is the assignee of record of the entire interest in the invention claimed in the application. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Mario Cloutier ceases to lawfully reside in the United States, (ii) Mario Cloutier's employment with Millenium Pharmaceuticals ceases or is terminated, or (iii) Mario Cloutier ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: March 1, 2005

A handwritten signature in black ink, appearing to read "Harry I. Moatz", written over a horizontal line.

**Harry I. Moatz
Director of Enrollment and Discipline**